The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

BackgroundImmune checkpoint inhibitor (ICI) monotherapy remains the standard of care for patients with previously treated non-small cell lung cancer. However, few reports have compared the clinical benefits of second-line ICIs alone with those of ICIs combined with other therapies, including anti-an...

Full description

Bibliographic Details
Main Authors: Ting Zhang, Xue Yang, Jing Zhao, Lixia Xia, Qiyuan Wang, Rui Jin, Lingxiao Zhou, Bin Zhang, Jun Zhao, Huijie Li, Wen Li, Yang Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor (ICI)
anti-angiogenic therapy
chemotherapy
non-small cell lung cancer (NSCLC)
lung immune prognostic index (LIPI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.690093/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.690093/full

Similar Items